Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
复制标题
DOI：
10.1158/1078-0432.ccr-04-0378
复制
发表时间：
2004-10-15
影响因子：
11.5
通讯作者：
Terstappen, LWMM
中科院分区：
文献类型：
--
作者：
Allard, WJ;Matera, J;Terstappen, LWMM
目的：本研究的目的是确定 CellSearch 系统的准确度、精密度和线性度，并评估健康受试者、非恶性疾病患者和各种转移性癌症患者每 7.5 mL 血液中循环肿瘤细胞 (CTC) 的数量。 实验设计：使用 CellSearch 系统对 7.5 mL 血液中的 CTC 进行计数。使用掺有肿瘤细胞系细胞的血液样本来确定分析准确性、重现性和线性。对 199 名非恶性肿瘤患者、964 名转移性癌症患者和 145 名健康捐献者的血液中 CTC 的患病率进行了测定。 结果：尖峰肿瘤细胞的计数在 5 至 1,142 个细胞范围内呈线性，平均回收率为；每个峰值水平大于或等于 85%。 344 名健康和非恶性疾病受试者中，只有 1 名 (0.3%) 每 7.5 mL 血液中的 CTC 大于或等于 2 个。在来自 964 名转移性癌症患者的 2,183 份血液样本中，CTC 范围为每 7.5 mL 0 至 23,618 个 CTC（平均每 7.5 mL 60 +/- 693 个 CTC），并且 36%（2,183 份样本中的 781 份）样本的 CTC 大于或等于 2 个。检测到大于或等于 2 个 CTC 的比例如下：前列腺癌 57%（188 例中的 107 例）、乳腺癌 37%（1,316 例中的 489 例）、卵巢癌 37%（53 例中的 20 例）、结直肠癌 30%（333 例中的 99 例）、肺癌 20%（168 例中的 34 例）和 26% （125 种中的 32 种）其他癌症。结论：CellSearch 系统可以在多个实验室之间进行标准化，并可用于确定 CTC 的临床效用。 CTC 在健康受试者和非恶性疾病患者中极为罕见，但在各种转移性癌中存在的频率范围很广。
Purpose: The purpose of this study was to determine the accuracy, precision, and linearity of the CellSearch system and evaluate the number of circulating tumor cells (CTCs) per 7.5 mL of blood in healthy subjects, patients with nonmalignant diseases, and patients with a variety of metastatic carcinomas.Experimental Design: The CellSearch system was used to enumerate CTCs in 7.5 mL of blood. Blood samples spiked with cells from tumor cell lines were used to establish analytical accuracy, reproducibility, and linearity. Prevalence of CTCs was determined in blood from 199 patients with nonmalignant diseases, 964 patients with metastatic carcinomas, and 145 healthy donors.Results: Enumeration of spiked tumor cells was linear over the range of 5 to 1,142 cells, with an average recovery of; greater than or equal to85% at each spike level. Only 1 of the 344 (0.3%) healthy and nonmalignant disease subjects had greater than or equal to2 CTCs per 7.5 mL of blood. In 2,183 blood samples from 964 metastatic carcinoma patients, CTCs ranged from 0 to 23,618 CTCs per 7.5 mL (mean, 60 +/- 693 CTCs per 7.5 mL), and 36% (781 of 2,183) of the specimens had greater than or equal to2 CTCs. Detection of greater than or equal to2 CTCs occurred at the following rates: 57% (107 of 188) of prostate cancers, 37% (489 of 1,316) of breast cancers, 37% (20 of 53) of ovarian cancers, 30% (99 of 333) of colorectal cancers, 20% (34 of 168) of lung cancers, and 26% (32 of 125) of other cancers.Conclusions: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs. CTCs are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.